The estimated Net Worth of James Andrew Iii Mc Ginness is at least $31.9 mil dollars as of 29 August 2024. James Ginness owns over 14,618 units of Cronos Inc stock worth over $31,867 and over the last few years James sold CRON stock worth over $0.
James has made over 1 trades of the Cronos Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently James exercised 14,618 units of CRON stock worth $31,867 on 29 August 2024.
The largest trade James's ever made was exercising 14,618 units of Cronos Inc stock on 29 August 2024 worth over $31,867. On average, James trades about 7,309 units every 0 days since 2023. As of 29 August 2024 James still owns at least 14,618 units of Cronos Inc stock.
You can see the complete history of James Ginness stock trades at the bottom of the page.
James's mailing address filed with the SEC is 4491 CONCESSION RD 12, , STAYNER, A6, L0M 1S0.
Over the last 4 years, insiders at Cronos Inc have traded over $30,495,757 worth of Cronos Inc stock and bought 1,848,320 units worth $4,899,192 . The most active insiders traders include Michael Ryan Gorenstein, Jason Marc Adler y Jeffrey David Jacobson. On average, Cronos Inc executives and independent directors trade stock every 15 days with the average trade being worth of $528,456. The most recent stock trade was executed by James Andrew Iii Mc Ginness on 29 August 2024, trading 14,618 units of CRON stock currently worth $31,867.
cronos group is a globally diversified and vertically integrated cannabis company with a presence across four continents. the company operates two wholly-owned canadian licensed producers regulated under health canada’s access to cannabis for medical purposes regulations: peace naturals project inc. (ontario), which was the first non-incumbent medical cannabis license granted by health canada, and original bc ltd. (british columbia), which is based in the okanagan valley. the company has multiple international production and distribution platforms: cronos israel and cronos australia. through an exclusive distribution agreement, cronos also has access to over 12,000 pharmacies in germany as the company focuses on building an international iconic brand portfolio and developing disruptive intellectual property.
Cronos Inc executives and other stock owners filed with the SEC include: